Summary

Asia Pacific Pneumococcal Vaccine Market is valued approximately USD 1.02 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.17% over the forecast period 2024-2032. The pneumococcal vaccine is a crucial immunization designed to protect against infections caused by the bacterium Streptococcus pneumoniae. This bacterium can lead to serious illnesses such as pneumonia, meningitis, and bacteremia. There are different types of pneumococcal vaccines available, including the pneumococcal conjugate vaccine (PCV) and the pneumococcal polysaccharide vaccine (PPSV). The key trend of Asia Pacific Pneumococcal Vaccine market in Asia Pacific is growing focus on healthcare infrastructure. Efforts to strengthen healthcare infrastructure, particularly in rural and underserved areas, have facilitated the distribution and administration of pneumococcal vaccines. Investments in cold chain storage, training of healthcare professionals, and logistical support have been crucial in improving vaccine delivery.

Moreover, the rising awareness among the population and government initiatives aimed at preventing infectious diseases have led to increased demand for pneumococcal vaccines. Governments across the Asia Pacific region is increasingly investing in vaccination programs to reduce the burden of pneumococcal diseases. Also, the Asia Pacific region experiences a significant burden of pneumococcal diseases, including pneumonia, meningitis, and septicemia. The high prevalence of these diseases drives the demand for pneumococcal vaccines as a preventive measure. Additionally, pharmaceutical companies are investing in research and development to develop more effective and affordable pneumococcal vaccines. These efforts have resulted in the development of newer vaccine formulations and technologies, driving market growth. However, the logistics and distribution challenges are expected to hinder the Asia Pacific Pneumococcal Vaccine market growth during the forecast period 2024-2032.

The key Countries considered for the Asia Pacific Pneumococcal Vaccine market study includes China, India, Japan, South Korea, Australia and Rest of Asia Pacific. In 2023, China was the largest regional market in terms of revenue. Government initiatives promoting vaccination programs, especially for children and elderly populations, could be driving the demand for pneumococcal vaccines. China has been expanding its immunization programs to reach more of its population, which would naturally include vaccines against pneumococcal diseases. Also, as China's economy continues to grow, there's anticipated to increase in healthcare expenditure, enabling more individuals and families to afford preventive healthcare measures such as vaccination. Moreover, India is expected to grow with the highest CAGR during the forecast period 2024-2032.

Major market player included in this report are:
Serum Institute of India Pvt
Beijing Minhai Biotechnology Co., Ltd
Walvax Biotechnology Co., Ltd
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10

The detailed segments and sub-segment of the market are explained below:
By Vaccine Type
Pneumococcal Conjugate Vaccine
Pneumococcal Polysaccharide Vaccine

By Product
Prevnar 13
Synflorix
Pneumovax 23
Vaxneuvance
Pneumosil
Other Products

By End-use
Public Sector
Private Sector
By Region:
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

ページTOPに戻る

Table of Contents

Chapter 1. Asia Pacific Pneumococcal Vaccine Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. Asia Pacific Pneumococcal Vaccine Market Size & Forecast (2022- 2032)
2.2. Regional Summary
2.3. Segmental Summary
2.3.1. By Vaccine Type
2.3.2. By Product
2.3.3. By End-use
2.4. Key Trends
2.5. Recession Impact
2.6. Analyst Recommendation & Conclusion
Chapter 3. Asia Pacific Pneumococcal Vaccine Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. Asia Pacific Pneumococcal Vaccine Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Asia Pacific Pneumococcal Vaccine Market Size & Forecasts by Vaccine Type 2022-2032
5.1. Pneumococcal Conjugate Vaccine
5.2. Pneumococcal Polysaccharide Vaccine
Chapter 6. Asia Pacific Pneumococcal Vaccine Market Size & Forecasts by Product 2022-2032
6.1. Prevnar 13
6.2. Synflorix
6.3. Pneumovax 23
6.4. Vaxneuvance
6.5. Pneumosil
6.6. Other Products
Chapter 7. Asia Pacific Pneumococcal Vaccine Market Size & Forecasts by End-use 2022-2032
7.1. Public Sector
7.2. Private Sector
Chapter 8. Asia Pacific Pneumococcal Vaccine Market Size & Forecasts by Country 2022-2032
8.1. China Pneumococcal Vaccine Market
8.1.1. Vaccine Type breakdown size & forecasts, 2022-2032
8.1.2. Product breakdown size & forecasts, 2022-2032
8.1.3. End-use breakdown size & forecasts, 2022-2032
8.2. India Pneumococcal Vaccine Market
8.3. Japan Pneumococcal Vaccine Market
8.4. Australia Pneumococcal Vaccine Market
8.5. South Korea Pneumococcal Vaccine Market
8.6. Rest of Asia Pacific Pneumococcal Vaccine Market
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. Company 1
9.1.2. Company 2
9.1.3. Company 3
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Serum Institute of India Pvt
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. Beijing Minhai Biotechnology Co., Ltd
9.3.3. Walvax Biotechnology Co., Ltd
9.3.4. Company 4
9.3.5. Company 5
9.3.6. Company 6
9.3.7. Company 7
9.3.8. Company 8
9.3.9. Company 9
9.3.10. Company 10
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes